Amedeo Smart

Free Medical Literature Service

 

Amedeo

Schizophrenia
  Free Subscription

Articles published in
Neuropsychopharmacology
    October 2026
  1. XIANG J, Ran J, Zhu P, Wang Y, et al
    Transdiagnostic mapping of common and specific regional homogeneity alterations across affective and psychotic disorders.
    Neuropsychopharmacology. 2026;51:2093-2101.
    >> Share

  2. AKULA N, Liu S, Shah S, Peddada TN, et al
    Allele-specific expression in the brain links genetic risk and cortical thinning in psychiatric disorders.
    Neuropsychopharmacology. 2026;51:1916-1923.
    >> Share

    September 2026
  3. ANKEETA A, Tripathi A, Pillai B, Ma Y, et al
    Correction: Blood and neuronal extracellular vesicle mitochondrial disruptions in schizophrenia.
    Neuropsychopharmacology. 2026 Sep 21. doi: 10.1038/s41386-026-02566.
    >> Share

  4. THEIS N, Rubin J, O'Rourke E, Bahuguna J, et al
    Temporal stability of functional network configurations and its relationship to cognition and psychopathology in early psychoses.
    Neuropsychopharmacology. 2026 Sep 12. doi: 10.1038/s41386-026-02544.
    >> Share

    August 2026
  5. MAXIMO JO, Richman J, Lahti AC
    Trajectories of psychotic symptoms and fronto-parietal resting state functional connectivity MRI following an antipsychotic trial in medication-naive first-episode psychosis patients.
    Neuropsychopharmacology. 2026 Aug 21. doi: 10.1038/s41386-026-02515.
    >> Share

  6. HUPALO S, Kupferschmidt DA, Ikegami A, Railing M, et al
    Altered thalamo-prefrontal synchrony dynamics during spatial working memory task performance in a SETD1A loss-of-function mouse model of schizophrenia predisposition.
    Neuropsychopharmacology. 2026 Aug 17. doi: 10.1038/s41386-026-02532.
    >> Share

  7. PUPI M, Papale AE, Calabro FJ, Raminfard S, et al
    7T magnetic resonance spectroscopic imaging of subcortical neurometabolites across antipsychotic treatment in acutely symptomatic early-phase schizophrenia spectrum disorders.
    Neuropsychopharmacology. 2026 Aug 10. doi: 10.1038/s41386-026-02522.
    >> Share

    July 2026
  8. GATTUSO JJ, Kamal A, Payet JM, Havaux K, et al
    Psilocybin produces amplified acute responses and sex-specific long-term increases in sensorimotor gating in the mGlu5 knockout mouse model of schizophrenia.
    Neuropsychopharmacology. 2026 Jul 18. doi: 10.1038/s41386-026-02501.
    >> Share

  9. KWON SH, Martinowich K
    Neuronal genetic risk within the multicellular landscape of schizophrenia.
    Neuropsychopharmacology. 2026 Jul 10. doi: 10.1038/s41386-026-02497.
    >> Share

  10. HINDLEY G, Mizuno Y, Beck K, Carreira Figueiredo I, et al
    Does a monoclonal antibody targeting immune cells affect glutamatergic level in schizophrenia? A multimodal PET/MRS brain imaging study.
    Neuropsychopharmacology. 2026 Jul 9. doi: 10.1038/s41386-026-02466.
    >> Share

  11. TRAYVICK J, Perlman G, Jonas KG, Donaldson KR, et al
    Auditory event-related potentials and psychosis dimensions.
    Neuropsychopharmacology. 2026 Jul 4. doi: 10.1038/s41386-026-02487.
    >> Share

    June 2026
  12. MAYER MR, Choo TH, Javitt DC, Kantrowitz JT, et al
    Serotonin type 3 receptor (5-HT(3)R) antagonists for negative symptoms and cognitive impairment associated with schizophrenia: a systematic review and meta-analysis.
    Neuropsychopharmacology. 2026 Jun 17. doi: 10.1038/s41386-026-02467.
    >> Share

  13. PARKER N, Koch E, Shadrin AA, Fuhrer J, et al
    Leveraging the genetics of psychiatric disorders to prioritize potential drug targets and compounds.
    Neuropsychopharmacology. 2026;51:1300-1309.
    >> Share

    April 2026
  14. CHANG X, Bryant L, Mena Ortega S, Howes O, et al
    A frontotemporal dementia-like phenotype in schizophrenia: links to striatal dopamine and iron accumulation.
    Neuropsychopharmacology. 2026 Apr 25. doi: 10.1038/s41386-026-02426.
    >> Share

  15. KHIN NA, Fan RH, Ge T, Klein HS, et al
    A phase 2 randomized controlled trial of luvadaxistat in treatment of adults with cognitive impairment associated with schizophrenia: results from the ERUDITE study.
    Neuropsychopharmacology. 2026 Apr 24. doi: 10.1038/s41386-026-02410.
    >> Share

  16. HORNG JE, McCrea LT, Batorsky RE, Bowen JJ, et al
    Functional genomic profiling of schizophrenia-associated genes reveals key microglial regulators.
    Neuropsychopharmacology. 2026 Apr 16. doi: 10.1038/s41386-026-02406.
    >> Share

  17. YANG BZ, He L, Liu TQ, Ma S, et al
    Causal links among gut microbiota, immune-inflammatory and compensatory immune-regulatory systems, and schizophrenia.
    Neuropsychopharmacology. 2026 Apr 15. doi: 10.1038/s41386-026-02407.
    >> Share

    March 2026
  18. QI G, Zhang Y, Wang YL, Anjum F, et al
    Putative glymphatic function and free water in schizophrenia: A 7T DTI study across psychosis stages.
    Neuropsychopharmacology. 2026 Mar 24. doi: 10.1038/s41386-026-02391.
    >> Share

    February 2026
  19. ONWORDI EC, Whitehurst T, Shatalina E, Mansur A, et al
    Whole brain grey matter synaptic terminal density, age and intellectual functioning in schizophrenia: an in vivo [(11)C]UCB-J positron emission tomography study.
    Neuropsychopharmacology. 2026 Feb 3. doi: 10.1038/s41386-026-02349.
    >> Share

    January 2026
  20. HE Z, He W, Chen Z, Wei W, et al
    Intrinsic connectivity patterns of striatal subfields predict individual dimensions of psychopathology and are associated with cholinergic and serotonergic neurotransmission in schizophrenia.
    Neuropsychopharmacology. 2026 Jan 17. doi: 10.1038/s41386-026-02354.
    >> Share

  21. ASIM A, Yang Y, Heilbronner U, Schulze T, et al
    The impact of collider bias on genetic prediction in psychotic disorders.
    Neuropsychopharmacology. 2026;51:430-439.
    >> Share

    December 2025
  22. HAZLETT EA, Fiore VG, Shafritz KM, Ng S, et al
    Aberrant effective connectivity during working memory performance in schizotypal personality disorder and schizophrenia: A spectrum approach.
    Neuropsychopharmacology. 2025 Dec 11. doi: 10.1038/s41386-025-02295.
    >> Share

    November 2025
  23. TARUMI R, Honda S, Cassidy C, Etani T, et al
    Associations of neuromelanin in the substantia nigra with antipsychotic response in schizophrenia.
    Neuropsychopharmacology. 2025 Nov 7. doi: 10.1038/s41386-025-02275.
    >> Share

    October 2025
  24. O'BRIEN KJ, Huque ZM, Pike MR, Smith EC, et al
    Synergistic pathways to psychosis: understanding developmental risk and resilience factors.
    Neuropsychopharmacology. 2025 Oct 10. doi: 10.1038/s41386-025-02261.
    >> Share

  25. CHATTERJEE S, Soria M, Norville ZC, Thompson KR, et al
    Preclinical efficacy of the muscarinic agonist ML-007 in psychosis models depends on both M(1) and M(4) receptors.
    Neuropsychopharmacology. 2025 Oct 4. doi: 10.1038/s41386-025-02256.
    >> Share

    September 2025
  26. GARCIA-CERRO S, Gomez-Garrido A, Soria FN, Loucera C, et al
    Clozapine induces perineuronal net remodeling in a developmental mouse model exhibiting schizophrenia-relevant phenotypes.
    Neuropsychopharmacology. 2025 Sep 25. doi: 10.1038/s41386-025-02210.
    >> Share

  27. GIRGIS RR, de la Fuente-Sandoval C, Lewis-Fernandez R, Reyes-Madrigal F, et al
    Concerted elevations of cortical and striatal glutamate and GABA in antipsychotic-free individuals at clinical high-risk for psychosis.
    Neuropsychopharmacology. 2025 Sep 25. doi: 10.1038/s41386-025-02251.
    >> Share

  28. HERMS EN, Wisner KM
    Moving from isolation to integration: a Bayesian multisensory perspective of interoception and psychosis.
    Neuropsychopharmacology. 2025 Sep 24. doi: 10.1038/s41386-025-02250.
    >> Share

  29. HOLMES DR
    From psychosis to creativity: a lived experience perspective on serious mental illness symptoms.
    Neuropsychopharmacology. 2025 Sep 10. doi: 10.1038/s41386-025-02212.
    >> Share

    August 2025
  30. BERSHAD AK
    For those with schizophrenia, does cannabidiol make cannabis use safer?
    Neuropsychopharmacology. 2025 Aug 26. doi: 10.1038/s41386-025-02199.
    >> Share

  31. ANKEETA A, Tripathi A, Pillai B, Ma Y, et al
    Blood and neuronal extracellular vesicle mitochondrial disruptions in schizophrenia.
    Neuropsychopharmacology. 2025 Aug 23. doi: 10.1038/s41386-025-02204.
    >> Share

  32. KU BS, Young JW
    Social environment as a determinant of mismatch negativity in early psychosis.
    Neuropsychopharmacology. 2025 Aug 19. doi: 10.1038/s41386-025-02195.
    >> Share

  33. FERLAND JN, Di Forti M
    Rewired realities: novel insights into the neurobiology of cannabis use disorder and psychosis.
    Neuropsychopharmacology. 2025 Aug 6. doi: 10.1038/s41386-025-02189.
    >> Share

  34. ULIANA DL, Walsh RA, Fabris D, Grace AA, et al
    Evenamide reverses schizophrenia-related dysfunction in a neurodevelopmental animal model.
    Neuropsychopharmacology. 2025 Aug 5. doi: 10.1038/s41386-025-02188.
    >> Share

    July 2025
  35. CHESNEY E, Oliver D, Sarma A, Lamper AD, et al
    Does cannabidiol reduce the adverse effects of cannabis in schizophrenia? A randomised, double-blind, cross-over trial.
    Neuropsychopharmacology. 2025 Jul 24. doi: 10.1038/s41386-025-02175.
    >> Share

  36. KAWATAKE-KUNO A, Leventhal MB, Morishita H
    Impact of early social isolation on social circuits and behavior: relevance to schizophrenia.
    Neuropsychopharmacology. 2025 Jul 4. doi: 10.1038/s41386-025-02156.
    >> Share

    May 2025
  37. HUANG H, Wang X, Qin X, Xu R, et al
    Distinct structural deficits in treatment-resistant schizophrenia and their putative neurotransmitter basis: a source-based morphometry analysis.
    Neuropsychopharmacology. 2025 May 28. doi: 10.1038/s41386-025-02135.
    >> Share

  38. KING VL, Hellemann G, Lahti AC, Defenderfer M, et al
    Cortical myelin mapping in antipsychotic medication-naive, first-episode psychosis patients.
    Neuropsychopharmacology. 2025 May 23. doi: 10.1038/s41386-025-02137.
    >> Share

    April 2025
  39. GOLDSMITH DR, Ning CS, Strauss GP, Gross RE, et al
    Inflammation is associated with avolition and reduced resting state functional connectivity in corticostriatal reward circuitry in patients with schizophrenia.
    Neuropsychopharmacology. 2025 Apr 24. doi: 10.1038/s41386-025-02114.
    >> Share

  40. KU BS, Hamilton H, Yuan Q, Parker DA, et al
    Neighborhood social fragmentation in relation to impaired mismatch negativity among youth at clinical high risk for psychosis and healthy comparisons.
    Neuropsychopharmacology. 2025 Apr 2. doi: 10.1038/s41386-025-02093.
    >> Share

    March 2025
  41. DHAMALA E, Rubio JM
    Persistent brain network signatures in psychosis: implications for diagnosis, prognosis, and treatment.
    Neuropsychopharmacology. 2025 Mar 5. doi: 10.1038/s41386-025-02079.
    >> Share

    February 2025
  42. DYBOWSKI FP, Scott DS, Tamminga CA
    Pharmacological reduction of reverse-translated hippocampal hyperactivity in mouse: relevance for psychosis.
    Neuropsychopharmacology. 2025 Feb 27. doi: 10.1038/s41386-025-02077.
    >> Share

  43. FOSTER ML, Ye J, Powers AR, Dvornek NC, et al
    Connectome-based predictive modeling of early and chronic psychosis symptoms.
    Neuropsychopharmacology. 2025 Feb 27. doi: 10.1038/s41386-025-02064.
    >> Share

  44. SAMSOM JN, Xu M, Avila A, Daskalakis AA, et al
    Protein interacting with C-kinase 1 (PICK1) regulates synaptic function and reversal learning in a mouse model for schizophrenia.
    Neuropsychopharmacology. 2025 Feb 22. doi: 10.1038/s41386-025-02072.
    >> Share

    November 2024
  45. ZHANG W, Wang L, Wu X, Yao L, et al
    Improved patient identification by incorporating symptom severity in deep learning using neuroanatomic images in first episode schizophrenia.
    Neuropsychopharmacology. 2024 Nov 6. doi: 10.1038/s41386-024-02021.
    >> Share

    September 2024
  46. BRAKATSELOS C, Polissidis A, Ntoulas G, Asprogerakas MZ, et al
    Multi-level therapeutic actions of cannabidiol in ketamine-induced schizophrenia psychopathology in male rats.
    Neuropsychopharmacology. 2024 Sep 6. doi: 10.1038/s41386-024-01977.
    >> Share

    August 2024
  47. SLIFSTEIN M, Qu W, Gil R, Weinstein JJ, et al
    Kappa opioid receptor availability predicts severity of anhedonia in schizophrenia.
    Neuropsychopharmacology. 2024 Aug 31. doi: 10.1038/s41386-024-01975.
    >> Share

    July 2024
  48. ABRAM SV, Hua JPY
    Pons connectivity correlates with neurophysiological and clinical signatures of predictive coding in psychosis.
    Neuropsychopharmacology. 2024 Jul 22. doi: 10.1038/s41386-024-01919.
    >> Share

  49. SMUCNY J, Carter CS
    Is treatment-resistant schizophrenia a neuroimmune condition? Meta-analytic evidence from magnetic resonance spectroscopy.
    Neuropsychopharmacology. 2024 Jul 18. doi: 10.1038/s41386-024-01932.
    >> Share

    June 2024
  50. JOHNSON EC, Austin-Zimmerman I, Thorpe HHA, Levey DF, et al
    Cross-ancestry genetic investigation of schizophrenia, cannabis use disorder, and tobacco smoking.
    Neuropsychopharmacology. 2024 Jun 21. doi: 10.1038/s41386-024-01886.
    >> Share

  51. CHENOWETH MJ
    Cracking the chicken and egg problem of schizophrenia and substance use: Genetic interplay between schizophrenia, cannabis use disorder, and tobacco smoking.
    Neuropsychopharmacology. 2024 Jun 11. doi: 10.1038/s41386-024-01898.
    >> Share

  52. KOCH E, Kampe A, Alver M, Siguretharson S, et al
    Polygenic liability for antipsychotic dosage and polypharmacy - a real-world registry and biobank study.
    Neuropsychopharmacology. 2024;49:1113-1119.
    >> Share

    May 2024
  53. PISANU C, Congiu D, Meloni A, Paribello P, et al
    Dissecting the genetic overlap between severe mental disorders and markers of cellular aging: Identification of pleiotropic genes and druggable targets.
    Neuropsychopharmacology. 2024;49:1033-1041.
    >> Share

    April 2024
  54. LIVINGSTON NR, Kiemes A, Devenyi GA, Knight S, et al
    Effects of diazepam on hippocampal blood flow in people at clinical high risk for psychosis.
    Neuropsychopharmacology. 2024 Apr 24. doi: 10.1038/s41386-024-01864.
    >> Share

    March 2024
  55. SCHOONOVER KE, Dienel SJ, Holly Bazmi H, Enwright JF 3rd, et al
    Altered excitatory and inhibitory ionotropic receptor subunit expression in the cortical visuospatial working memory network in schizophrenia.
    Neuropsychopharmacology. 2024 Mar 28. doi: 10.1038/s41386-024-01854.
    >> Share

  56. HUANG AS, Kang K, Vandekar S, Rogers BP, et al
    Lifespan development of thalamic nuclei and characterizing thalamic nuclei abnormalities in schizophrenia using normative modeling.
    Neuropsychopharmacology. 2024 Mar 13. doi: 10.1038/s41386-024-01837.
    >> Share

  57. SEITZ-HOLLAND J, Aleman-Gomez Y, Cho KIK, Pasternak O, et al
    Matrix metalloproteinase 9 (MMP-9) activity, hippocampal extracellular free water, and cognitive deficits are associated with each other in early phase psychosis.
    Neuropsychopharmacology. 2024 Mar 2. doi: 10.1038/s41386-024-01814.
    >> Share

    February 2024
  58. CABRERA-MENDOZA B, Aydin N, Fries GR, Docherty AR, et al
    Estimating the direct effects of the genetic liabilities to bipolar disorder, schizophrenia, and behavioral traits on suicide attempt using a multivariable Mendelian randomization approach.
    Neuropsychopharmacology. 2024 Feb 23. doi: 10.1038/s41386-024-01833.
    >> Share

  59. TRUONG TTT, Liu ZSJ, Panizzutti B, Kim JH, et al
    Network-based drug repurposing for schizophrenia.
    Neuropsychopharmacology. 2024 Feb 6. doi: 10.1038/s41386-024-01805.
    >> Share

    January 2024
  60. PAUL SM, Potter WZ
    Finding new and better treatments for psychiatric disorders.
    Neuropsychopharmacology. 2024;49:3-9.
    >> Share

  61. HANSON JE, Yuan H, Perszyk RE, Banke TG, et al
    Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry.
    Neuropsychopharmacology. 2024;49:51-66.
    >> Share

    December 2023
  62. ARIME Y, Saitoh Y, Ishikawa M, Kamiyoshihara C, et al
    Activation of prefrontal parvalbumin interneurons ameliorates working memory deficit even under clinically comparable antipsychotic treatment in a mouse model of schizophrenia.
    Neuropsychopharmacology. 2023 Dec 4. doi: 10.1038/s41386-023-01769.
    >> Share

    October 2023
  63. WANG DM, Chen DC, Xiu MH, Wang L, et al
    A double-blind, randomized controlled study of the effects of celecoxib on clinical symptoms and cognitive impairment in patients with drug-naive first episode schizophrenia: pharmacogenetic impact of cyclooxygenase-2 functional polymorphisms.
    Neuropsychopharmacology. 2023 Oct 30. doi: 10.1038/s41386-023-01760.
    >> Share

  64. ROESKE MJ, McHugo M, Rogers B, Armstrong K, et al
    Modulation of hippocampal activity in schizophrenia with levetiracetam: a randomized, double-blind, cross-over, placebo-controlled trial.
    Neuropsychopharmacology. 2023 Oct 13. doi: 10.1038/s41386-023-01730.
    >> Share

    September 2023
  65. FAN L, Liang L, Wang Y, Ma X, et al
    Glutamatergic basis of antipsychotic response in first-episode psychosis: a dual voxel study of the anterior cingulate cortex.
    Neuropsychopharmacology. 2023 Sep 26. doi: 10.1038/s41386-023-01741.
    >> Share

  66. ZHOU DY, Su X, Wu Y, Yang Y, et al
    Decreased CNNM2 expression in prefrontal cortex affects sensorimotor gating function, cognition, dendritic spine morphogenesis and risk of schizophrenia.
    Neuropsychopharmacology. 2023 Sep 15. doi: 10.1038/s41386-023-01732.
    >> Share

  67. RABIN RA, Palaniyappan L
    Brain health in ethnically minority youth at risk for psychosis.
    Neuropsychopharmacology. 2023 Sep 4. doi: 10.1038/s41386-023-01719.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016